Idera Pharmaceuticals has acquired 1 company, including 1 in the last 5 years.
Idera Pharmaceuticals has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).
505 Eagleview Boulevard, Suite 212,
Exton, Pennsylvania
19341
United States,
www.iderapharma.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2022-09-28 |
Aceragen · Life Science
Research Triangle Park, North Carolina · www.aceragen.com Aceragen is a biopharmaceutical company developing innovative therapeutics for rare and orphan diseases. The Company is advancing ACG-801 (rhAC) as an investigational enzyme replacement therapy for the treatment of patients with Farber disease and potentially other diseases associated with the dysregulation of ceramide metabolism, including cystic fibrosis. Its other development lead is ACG-721, an oral small molecule candidate for cystic fibrosis pulmonary exacerbations and related orphan infectious diseases. Aceragen is based in Research Triangle Park, North Carolina. Advisors: Fenwick & West , Wedbush Securities |
- | Add-on Acquisition |
Idera Pharmaceuticals, Inc.
|
- |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
